Remdesivir for Severe COVID-19: Clinical Trial Results
Remdesivir, a nucleotide analog antiviral, significantly reduces recovery time for hospitalized adults with severe COVID-19. In a randomized, double-blind, placebo-controlled trial, the drug inhibits viral replication, allowing patients to stabilize ... Read More